AstraZeneca to acquire US-based Alexion Pharmaceuticals for $39bn
AstraZeneca would generate significant value from the acquisition by expanding Alexion's commercial reach and pipeline development
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Dec 20
AstraZeneca would generate significant value from the acquisition by expanding Alexion's commercial reach and pipeline development
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Dec 20
Leqvio claimed to be the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol (LDL-C) lowering treatment…
11 Dec 20
The acquisition will help expand Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumours
11 Dec 20
With the acquisition, Gilead will get access to MYR’s advanced chronic Hepatitis Delta Virus (HDV) treatment Hepcludex
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
10 Dec 20
Exscientia intends to use its AI-based Centaur platforms for genome scale AI-drug discovery and address critical global health…
10 Dec 20
Health Canada authorisation is based on Pfizer and BioNTech’s regulatory application, filed under the rolling submission regulatory pathway
09 Dec 20
In the interim analysis, the vaccine showed efficacy in preventing Covid-19, with no severe cases or hospitalisations after…
08 Dec 20
INO-4800 is an advanced prophylactic DNA vaccine candidate, designed to work against the activity of SARS-CoV-2, the virus…
08 Dec 20
Pfizer will leverage its extensive data and expertise, while PostEra its technology capabilities to advance the preclinical drug…
07 Dec 20
Sinovac will use the funding to further develop and expand the manufacturing capacity of its vaccine candidate CoronaVac